Purchase of pharmaceuticals which treat the underlying cause of cystic fibrosis (CFTR modulators)

Hankinnan yleistiedot

15 - Vapaaehtoista ennakkoavoimuutta (ex ante) koskeva ilmoitus (15)
Neuvottelumenettely ilman edeltävää tarjouskilpailukutsua
4.10.2018 10.18 (GMT+03:00)

Hankintayksikkö

Amgros I/S Amgros I/S
Jon Bjergfelt Jon Bjergfelt
Dampfærgevej 22
2100 København Ø
Tanska

Hankintapäätös

Cystic fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused by the presence of mutations in both copies of the gene for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein. Today, patients with cystic fibrosis are mainly treated with pharmaceuticals which reduce the symptoms of cystic fibrosis without treating their underlying cause. Amgros wishes to enter into a contract ensuring that public hospitals in Denmark, Greenland and the Faroe Islands will be able to offer all their cystic fibrosis patients treatment with pharmaceuticals, which treat the underlying cause of cystic fibrosis (CFTR modulators).

Mercell Suomi Oy

Osa Mercell-ryhmää, Euroopan johtavaa hankintapalvelujen sekä sähköisen kilpailutusjärjestelman tuottajaa.

Yleistä hankinnoista

Hankintalaki
TED

Yhteydenotto

Klikkaa tästä asiakaspalveluun

+358 207 528 600